A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder

Inclusion Criteria:

- Able to understand and provide written informed consent.

- Age 19-60, inclusive.

- Diagnosis documented according to DSM-IV of OCD.

- Exhibits moderate to severe OCD symptoms and a minimum score of 16 or greater -YBOCS
at screening.

- Willing and able to discontinue current medications taken for the treatment of OCD.

- Able to attend and participate in all study visits.

- Agree to continue if in current psychosocial therapy throughout the remainder of the
study.

- If female and of child-bearing potential, willing to use an acceptable method of
birth control for the duration of the study.

- If male, willing to use barrier method of birth control or had previous vasectomy.

Exclusion Criteria:

- Have other DSM-IV Axis I diagnoses.

- Pregnant as confirmed by urine analysis, or lactating, or unwilling to comply with
use of contraception.

- Unwilling or unable to washout (discontinue) from prohibited medications such as
antidepressants (See Appendix 2).

- Depression symptoms with a score of 15 or greater on the MADRS at screening.

- Current suicidal ideation or plan within the last 30 days.

- Have a medical condition which, in the opinion of the investigator, makes study
participation unsafe or noncompliant.

- Abnormal physical exam or laboratory values which, in the opinion of the
investigator, makes study participation unsafe or may require introduction of
concomitant medications during the course of the study.

- Benzodiazepine and/or similar sedative-hypnotic or anxiolytic use or abuse within 15
days of potential flumazenil treatment: patients must not be habituated to
benzodiazepines and must provide a urine sample that is negative for benzodiazepines,
must not be taking supra-therapeutic doses of zolpidem (AmbienTM) or zaleplon
(SonataTM ). (See Appendix 2).

- Patients who are taking Phenobarbital for a documented seizure disorder can be
admitted. Patients with a seizure disorder being managed with clonazepam (KlonopinTM
) or other benzodiazepine cannot participate, patients must not be taking TCA,
lithium, methylxanthines, isoniazid, propoxyphene, monoamine oxidase inhibitors,
bupropion HCL, and cyclosporine. (See Appendix 2).

- Previously treated with flumazenil for OCD.

- AIDS as determined by self-report.